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Available online xxxxBipolar disorder is one of two major psychotic disorders together with schizophrenia and causes severe psycho-
social disturbance. Lack of adequate animalmodels hampers development of newmood stabilizers.Weproposed
a mitochondrial dysfunction hypothesis and have been studying the neurobiology of bipolar disorder based on
this hypothesis. We showed that deletions of mitochondrial DNA (ΔmtDNA) play a pathophysiological role at
least in some patients with bipolar disorder possibly by affecting intracellular calcium regulation. Mutant poly-
merase γ transgenic mice that accumulate ΔmtDNA in the brain showed recurrent spontaneous depression-
like episodes which were prevented by a serotonin-selective reuptake inhibitor and worsened by lithium with-
drawal. The animal model would be useful to develop new mood stabilizers.
© 2016 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Animal model1. Introduction
Bipolar disorder is a major mental disorder showing manic and de-
pressive episodes, which frequently accompany psychotic symptoms
(Goodwin and Jamison, 2007). Because genetic factors are known to
contribute to this disorder based on twin studies among others (Kato,
2015), genetics-based animal models would be useful to understand
its neurobiology. Because causative genes of bipolar disorder have not
been identiﬁed yet, animal models of Mendelian diseases that frequent-
ly have comorbid bipolar disorder, such as Darier's disease (Nakamura
et al., 2016),Wolfram disease (Kato et al., 2008), andmitochondrial dis-
ease (Kasahara et al., 2016), would be one strategy. In this review, we
summarize our ongoing research project of neurobiological basis of bi-
polar disorder based on the mitochondrial dysfunction hypothesis.
2. Mitochondrial disease and bipolar disorder
In 1990's, we had studied the brain phosphorous metabolism in pa-
tients with bipolar disorder using phosphorus-31 magnetic resonance
spectroscopy (31P-MRS) and found that phosphocreatinewasdecreased
in the frontal lobe of patients with bipolar depression (Kato et al., 1992,
1994), decrease of phosphocreatine in the occipital cortex associated
with photic stimulation was enhanced in a subgroup of patients
(Murashita et al., 2000), intracellular pH in the frontal lobe (Kato et
al., 1993, 1998a) and whole brain (Hamakawa et al., 2004) wass, RIKEN Brain Science Institute,
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16.10.037decreased in the euthymic state. Decrease of phosphocreatine
(Barbiroli et al., 1993) and enhanced response of phosphocreatine to
photic stimulation (Kato et al., 1998b) was also reported in patients
with mitochondrial diseases, and thus we focused on the possible role
of mitochondrial dysfunction in bipolar disorder. Although the results
of recent 31P-MRS studies are not always consistent with each other,
they also show some abnormalities of energymetabolism in bipolar dis-
order or improvement by treatment (Dudley et al., 2015, 2016; Jensen
et al., 2008; Shi et al., 2012, 2015; Sikoglu et al., 2013; Stork and
Renshaw, 2005; Weber et al., 2013).
After the proposal of mitochondrial dysfunction hypothesis of bipo-
lar disorder, three groups performed structured interviews in patients
with mitochondrial diseases (Fattal et al., 2007; Inczedy-Farkas et al.,
2012; Mancuso et al., 2013) and reported that the prevalence of bipolar
disorder in mitochondrial diseases is 16–21%, nearly 20 times higher
than general population (Goodwin and Jamison, 2007). This suggests
that having mitochondrial disease is a strong risk factor for bipolar
disorder.
3. Evidence of mitochondrial DNA (mtDNA) deletion
Among mitochondrial diseases, chronic progressive
ophthalmoplegia (CPEO) is an adult onset disease characterized by ac-
cumulation of partially deleted mitochondrial DNA (ΔmtDNA). In an
autopsied case of CPEO with comorbid recurrent severe retarded de-
pression, more ΔmtDNAwas accumulated in the brain than in muscles,
suggesting that the phenotype caused by accumulation of ΔmtDNA in
the brain includes recurrent depression (Suomalainen et al., 1992).
Stimulated by this report, we quantiﬁed the levels of ΔmtDNA in thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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was signiﬁcantly increased (Kato et al., 1997). Although this ﬁnding
was later replicated by another group (Sequeira et al., 2012), theﬁnding
is not always consistent across samples and brain regions (Mamdani et
al., 2014). A report of a family of CPEOwithΔmtDNA, inwhich all affect-
edmembers had bipolar disorder, also supported the role ofΔmtDNA in
bipolar disorder (Mancuso et al., 2008).
Initially, we also focused on the association of bipolar disorder with
mtDNA polymorphisms (Kato et al., 2001) and showed that mtDNA
10398 polymorphism,whichwas associatedwith bipolar disorder, is as-
sociatedwithmitochondrial calcium signaling (Kazuno et al., 2006).We
also reported a genetic association of a complex I subunit gene with bi-
polar disorder (Washizuka et al., 2004). However, later it was revealed
that genetic association studies in a modest number of samples can
show false positive ﬁndings (Chanock et al., 2007), and recent genome
wide association studies (GWAS) also suggested that the statistical
threshold to observe genuine genetic association should be more con-
servative. To examine whether or not mtDNA polymorphisms are asso-
ciated with bipolar disorder, tens of thousands of samples should be
examined. Most recent GWAS including 9784 bipolar patients, in
which mtDNA is not considered, did not show association with mito-
chondria related genes (Hou et al., 2016). Re-analysis of GWAS data
did not show signiﬁcant association of mtDNA polymorphisms with bi-
polar disorder (Sequeira et al., 2012).We should await the results of fur-
ther large scale GWAS to conclude whether or not mtDNA
polymorphisms or polymorphisms of other mitochondria-related
genes are associated with bipolar disorder.
4. Mitochondrial dysfunction and calcium signaling
Based on the initial ﬁndings, we proposed mitochondrial dysfunc-
tion hypothesis of bipolar disorder in 2000 (Kato and Kato, 2000). In
this hypothesis,we proposed thatmtDNAmutations aswell as common
variationsmay confer a risk of bipolar disorder by affecting intracellular
calcium signaling systems. In spite that calcium levels are maintained
low in cells, higher concentration of calcium is accumulated in two or-
ganelles, mitochondria and endoplasmic reticulum (De Stefani et al.,
2016), where calcium released from endoplasmic reticulum is taken
up by mitochondria (Fig. 1). Elevation of intracellular calcium levels
has been reported in blood cells (Warsh et al., 2004). Lithium, the
most establishedmood stabilizer, acts on intracellular calcium signaling
by inhibiting inositol monophosphatase and upregulatingmitochondri-
al Bcl-2 on the mitochondrial outer membrane (Chen et al., 1999).
GWAS showed association of bipolar disorder with CACNA1C, encoding
α1C subunit of voltage gated calcium channel (Ferreira et al., 2008).
Exome or whole genome sequencing also suggested a possible role ofFig. 1. Role of mitochondria in intracellular calcium signaling. Intracellular calcium level is
maintained low, but two organelles, endoplasmic reticulum and mitochondria, have high
levels of calcium. Mendelian diseases that accompany bipolar disorder are the diseases of
these two organelles. GPCR, G protein coupled receptor; PIP2, Phosphatidylinositol 4,5-
bisphosphate; I-1-P, inositol 1-phosphate; IP3. Inositol triphosphate; IP3-R, inositol
triphosphate receptor; Bcl-2, B-cell lymphoma 2.
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Matoba et al., 2016), though they did not show mutations signiﬁcantly
associated with bipolar disorder at the genome wide signiﬁcance level.
These ﬁndings altogether suggest a role of intracellular calcium signal-
ing in bipolar disorder. Genetic factors, such as rare transmitted muta-
tions, de novo mutations, and polymorphisms, may contribute to
dysfunctional intracellular calciumsignaling in bipolar disorder, andmi-
tochondria-related genes affecting mitochondrial calcium signaling
would be one of these factors.
5. Multiple lines of evidence of mitochondrial dysfunction
Since then, numerous studies onmitochondrial dysfunction in bipo-
lar disorder have been published. Downregulation of mitochondria-re-
lated genes (Konradi et al., 2004; Sun et al., 2006) and upregulation of
a subset of mitochondria-related genes (Iwamoto et al., 2005) in post-
mortem brains, increase of lactate in the brain (Dager et al., 2004), de-
crease of complex I in postmortem brains (Andreazza et al., 2010),
abnormal mitochondrial structure in cells of bipolar patients (Cataldo
et al., 2010), and elevation of isocitrate in cerebrospinal ﬂuid associated
with impaired function of isocitrate dehydrogenase (Yoshimi et al.,
2016). A recent study showed that neurons derived from induced plu-
ripotent stem cells (iPSCs) of patients with bipolar disorder had hyper-
excitability associated with upregulation of mitochondrial genes,
increased mitochondrial membrane potential, and smaller size of mito-
chondria (Mertens et al., 2015). In addition to the landmark studies
noted above, numerous studies have been reported in this area, and a
PubMed search by “(mitochondria OR mitochondrial) and (bipolar dis-
order)” returns 325 papers (August 30/2016).
6. An animal model of mitochondrial DNA deletions in neurons
To develop an animal model of bipolar disorder based on mitochon-
drial dysfunction hypothesis, we focused on the accumulation of
ΔmtDNA in the brain, which is observed in patients with bipolar disor-
der and CPEO. To this end, we introduced a point mutation, D181A, in
polymerase γ (Polg1), the mtDNA polymerase, to remove exonuclease
activity and generateΔmtDNA (Kasahara et al., 2006). After we ﬁnished
the generation of mice with neuron-speciﬁc mutant Polg1, it was dis-
covered that POLG1 is one of causative genes of CPEOwith comorbid de-
pression (Van Goethem et al., 2001). Although knock in mice of D257A
mutation of Polg1 (Kujoth et al., 2005; Trifunovic et al., 2004) were also
reported, these mice show muscular impairment and are not suitable
for behavioral analysis (Fuke et al., 2014). The neuron speciﬁc transgen-
ic mice of D181A mutation of Polg1 (mPolg1 Tg mice) showed accumu-
lation of ΔmtDNA speciﬁcally in the brain. They did not show gross
abnormality in sensorimotor functions and learning and memory. The
mPolg1 Tg mice were found to have intracellular calcium signaling ab-
normality, shown by attenuation of G-protein-coupled receptor-medi-
ated calcium increase in hippocampal neurons (Kubota et al., 2006).
7. Behavioral phenotypes of mutant Polg1 transgenic mice
By an extensive behavioral analysis, we found that the mPolg1 Tg
mice show altered intra-day wheel running activity rhythm (Kasahara
et al., 2006). This was improved by electroconvulsive stimulation
(Kasahara et al., 2008). Furthermore, by observing the wheel running
activity for onemonth, we found that femalemPolg1 Tgmice show ﬂuc-
tuation ofwheel running activity associatedwith estrous cycle. Thiswas
ﬂattened by lithium treatment.
We further extended the length of behavioral observation to more
than half a year (Kasahara et al., 2016). The female mice showed recur-
rent spontaneous hypoactivity episodes, lasting approximately 2weeks.
This disappeared after ovariectomy, suggesting a role for female hor-
mones. It is well known that prevalence of depression is twice as high
in females than males, and women with bipolar disorder experiencer: Mitochondrial dysfunction hypothesis and beyond, Schizophr. Res.
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mechanisms proposed to explain the female bias is “limbic system hy-
peractivity” (Parker and Brotchie, 2010)where emotional dysregulation
may be caused by high binding of gonadal steroids in the limbic system
(Rainbow et al., 1982). The mechanism of female only depression-like
episodes and their potential relationship between hormonal control of
depression episodes will require future study.
There is no consensus how we can assess whether or not the ob-
served hypoactivity episode is “depressive episode”. Thus, we simply
thought that Diagnostic and Statistical Manual of Mental Disorders,
ﬁfth edition (DSM-5) (American Psychiatric Association, 2013) is the
de-facto standard of depressive episodes. Of course, there are numerous
differences in behavior between humans and mice. Furthermore, we
cannot communicate with mice by language and thus subjective symp-
toms such as depressive mood, guilty feeling, and suicidal ideation, can
never be assessed in mice. However, other items of DSM-5 criteria of
major depression refer to more objective signs such as sleep and appe-
tite. Thus, we assessed 6 out of 9 items of criteria A and criteria B of
major depressive episode.
Among criteria A, diminished interest or pleasure was assessed by
comparing wheel running activity which is hedonic activity, and home
cage activity. The mice showed normal home cage activity but showed
reduced wheel running activity, suggesting that the mice had anhedo-
nia. During the episodes, the mice ate more food and showed weight
gain. Electroencephalography (EEG) recording suggested that the mice
show increased sleep during dark period (active phase) and decreased
total sleep. By measuring the speed of wheel running, the mice in the
episodes showed slower movement, suggesting psychomotor retarda-
tion. A treadmill test showed that the mice showed fatigability during
the episode. Thus, 5 of the 9 items of A criteria of major depression
were met. On the other hand, the other item, “diminished concentra-
tion” was assessed by ﬁve-choice serial reaction time test. The mice
showed the same performance during the episodes. Thus, the mice in
the episode did not have diminished concentration. This also indicates
that the mice in the episode did not have consciousness disturbance.
The criterion B refers to the impaired social and occupational life. For
this item, we performed pup retrieval assay. Whereas majority of wild
type mice and the mPolg1 Tg mice in the euthymic state retrieved all
three pups in the home cage, the mPolg1 Tg mice in the episode re-
trieved signiﬁcantly less number of pups. This ﬁnding suggests that
themPolg1 Tgmice in the episode showed impaired social function. Col-
lectively, we concluded that the episode observed in mPolg1 Tg mice
satisﬁes the DSM-5 criteria of major depressive episode and is equiva-
lent to the depressive episode in humans (Kasahara et al., 2016).
We also found that a selective serotonin reuptake inhibitor,
escitalopram, inhibited depressive episodes, and lithiumwithdrawal in-
duced depressive episodes (Kasahara et al., 2016). We previously
showed that administration of amitriptyline, a tricyclic antidepressant,
induced manic like behavioral change (Kasahara et al., 2006). We also
examined the levels of corticosterone, and found that excretion of corti-
costerone increased during the episode. Bymeasuring the body temper-
ature, the mPolg1 Tg mice was found to show diminished intraday
ﬂuctuation of body temperaturewith higher average body temperature,
which is similar to the ﬁndings in human depression (Tsujimoto et al.,
1990).
8. The animal model meets three validity criteria
Collectively, we concluded that the mPolg1 Tg mice satisﬁes three
validity criteria of animal model; construct validity, that is similarities
of the mechanisms between the model and the disease, face validity,
commonalties between the behavioral features of the model and those
of the human disorder, and predictive validity, the efﬁcacy of human
drugs for the phenotype of the model animal. Though the mice did
not show any spontaneousmanic or hypomanic episodes, tricyclic anti-
depressant-inducedmanic like behavioral changes and atypical featuresPlease cite this article as: Kato, T., Neurobiological basis of bipolar disorde
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that the mice might have “bipolar spectrum”.9. Responsible brain region
Though we initially explained as if “mitochondrial dysfunction hy-
pothesis” is speciﬁc to bipolar disorder, it is not at all true. Indeed, mito-
chondrial dysfunction is a risk factor not only for bipolar disorder but
also for other medical diseases such as diabetes mellitus (Kadowaki et
al., 1994) and Parkinson's disease (Orth and Schapira, 2002).
People tend to eat too much in the modern food-rich environment.
Although there are several hormones to increase blood glucose level,
only one, insulin, can decrease it. Thus, pancreatic islet is Achilles' heel
of humans in themodern life. If a person has a latentmitochondrial dys-
function, the ﬁrst symptom might become apparent at the vulnerable
point, such as pancreatic islet. In the case of Parkinson's disease, produc-
tion of dopamine causes oxidative stress, and thus dopamine neurons
by its nature should have vulnerability. Associated with elongation of
human life span, mitochondrial dysfunction of such vulnerable point
might cause a disease in susceptible individuals.
If this speculation is true, which region of the brain is responsible for
bipolar disorder associated withmitochondrial dysfunction? In the case
of Parkinson's disease, accumulation ofΔmtDNA in substantia nigrawas
reported (Bender et al., 2006). Vice versa, wemay be able to identify the
brain region responsible for bipolar disorder, an equivalent of substantia
nigra in Parkinson's disease, by searching for the brain region accumu-
latingΔmtDNA. Thus,we performed comprehensive search for brain re-
gion(s) accumulating ΔmtDNA in the brain of mPolg1 Tg mice. We
identiﬁed that emotion related neural circuit such as medial prefrontal
cortex, nucleus accumbens and amygdala, accumulated relatively high
amount of ΔmtDNA. However, highest level of ΔmtDNA was detected
in paraventricular thalamic nucleus (PVT).10. Thepossible role of paraventricular thalamic nucleus (PVT) in bi-
polar disorder
PVT receives input from hypothalamic CRH (corticotropin releasing
hormone) neurons, suprachiasmatic nucleus, and dorsal raphe seroto-
nergic neurons, and send output to anterior cingulate cortex, nucleus
accumbens and amygdala (Hsu et al., 2014; Kirouac, 2015). Although
PVT itself has not been a strong candidate region of mood disorders, it
has connection to many candidate regions of mood disorders. The role
of PVT in regulation of emotion is recently drawing attention, and its
role in retrieval of fear memory (Do-Monte et al., 2015) and opiate
withdrawal (Zhu et al., 2016) have been reported by optogenetic ma-
nipulation of speciﬁc circuits involving PVT.
To test whether there is causal relationship between PVT dysfunc-
tion and depressive episodes, we functionally knocked down PVT by ex-
pressing tetanus toxin that impairs neural transmission in PVT by Cre-
loxP system (Kasahara et al., 2016). We found that the mice showed
the hypoactivity episodes similar tomPolg Tgmice. This suggest that ac-
cumulation of mtDNA in PVT has a pathophysiological role in depres-
sion-like behavior in mPolg Tg mice.
However, it is still not known whether PVT dysfunction plays a role
in human disease. Thus,we performed immunostaining of the thalamus
sections of patients with CPEO and mood symptoms. We found that
COX (cytochrome oxidase) negative cells, lacking in COX, a mtDNA-de-
rived protein, are abundant in paraventricular thalamus in those
patients.
Collectively, these ﬁndings suggest that dysfunction of PVT associat-
ed with mitochondrial dysfunction is causative for mood episodes at
least in patients with mitochondrial disease. It should be veriﬁed
whether some of patients with bipolar disorder or recurrent depression
without mitochondrial diseases also have dysfunction of PVT.r: Mitochondrial dysfunction hypothesis and beyond, Schizophr. Res.
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be useful for diagnosis. However, human PVTmay be too small to be vis-
ible by current neuroimaging technologies.
11. Conclusion
Starting frommagnetic resonance spectroscopic studies, subsequent
genetic analysis, postmortem brain studies, and animal model studies
altogether supported the role of mitochondrial dysfunction in bipolar
disorder. However, because mitochondrial dysfunction is not speciﬁc
to bipolar disorder,we should next focus onwhichneural circuit is dam-
aged by mitochondrial dysfunction. Thus, the study of mitochondrial
dysfunction of bipolar disorder should proceed to the next step. Our
study has already indicated that paraventricular thalamic nucleus is a
candidate brain region.
The genetics-based animal model generated in this study would be
useful to develop new mood stabilizers. Previously, there has been no
animal model to show spontaneous recurrent mood episodes, and
thus there was no method to screen candidate mood stabilizer to
show prophylactic effect for mood episodes. The mPolg Tg mouse is
the ﬁrst animal model showing spontaneous recurrent depressive epi-
sodes, which responded to existing anti-depression treatments. Thus,
the model mice would be helpful to develop new mood stabilizers or
antidepressants. We have already searched for candidate drug targets
by gene expression analysis of the model mice and postmortem brains
of patients with bipolar disorder (Kubota et al., 2010). Further studies
to identify promising lead compounds and search for companion diag-
nostic methods using themodelmicewill be needed to improve clinical
practice of bipolar disorder based on neurobiology of this disorder.
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